CAS 1386874-06-1

2H-Imidazo[4,5-c]quinolin-2-one, 1,3-dihydro-8-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(2S)-2-methoxypropyl]-3-methyl-

CAS : 1386874-06-1

Formule : C₂₃H₂₆N₄O₃

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 406.4775

Ref: IN-DA001900

Samotolisib

CAS : 1386874-06-1

Samotolisib

Formule : C₂₃H₂₆N₄O₃

Degré de pureté : ≥98%

Masse moléculaire : 406.48

Ref: 54-BUP13397

Samotolisib

CAS : 1386874-06-1

(S)-8-(5-(2-Hydroxypropan-2-yl)pyridin-3-yl)-1-(2-methoxypropyl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one

Formule : C₂₃H₂₆N₄O₃

Degré de pureté : 98%

Masse moléculaire : 406.48

Ref: IN-DG630209

Samotolisib

CAS : 1386874-06-1

Samotolisib (LY3023414) inhibits PI3K, DNA-PK, mTOR; tested for solid tumors including breast and colon cancer.

Formule : C₂₃H₂₆N₄O₃

Degré de pureté : 98.41% - 99.69%

Couleur et forme : Solid

Masse moléculaire : 406.48

Ref: TM-T6883

Samotolisib

CAS : 1386874-06-1

Degré de pureté : 98%

Masse moléculaire : 406.2

Ref: 10-F980066

Samotolisib

CAS : 1386874-06-1

Samotolisib is a novel drug that has been shown to inhibit tumor growth in vivo. Samotolisib was effective against tumors in a mouse xenograft model, as well as against both skin and bone cancer in mice. The molecular docking analysis suggests that samotolisib binds to the ATP-binding site of the enzyme ribonucleotide reductase (RNR), thereby inhibiting the production of DNA precursors required for protein synthesis. This inhibition leads to apoptosis and necrosis of tumor cells. Samotolisib has also been shown to induce autophagy and apoptosis in cultured human skin cells, suggesting it may have potential for treating skin cancers.

Formule : C₂₃H₂₆N₄O₃

Degré de pureté : Min. 95%

Masse moléculaire : 406.48 g/mol

Ref: 3D-LFC87406